Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®

Inclusion Criteria: * Subjects (male of female) ≥ 18 years of age able to give informed consent to the study. * Subjects with non-myeloid malignancies * Receiving chemotherapy as part of their cancer treatment with at least 4 weeks of treatment remaining. * Screening visit central laboratory hemoglobin (Hgb) ≤11 g/dL, but ≥8 g/dL. * Ferritin between 100 and 800 ng/mL and transferrin saturation (TSAT) =\<35% * Subjects must have Eastern Coopertative Oncology Group (ECOG) performance status of 0-2. * Life expectancy of at least 6 months. * Demonstrate the ability to understand the requirements of the study, willingness to abide by study restrictions and to return for the required assessments. Exclusion Criteria: * Previous participation in a ferric carboxymaltose clinical trial. * Known hypersensitivity reaction to any component of ferric carboxymaltose. * Subjects with overt bleeding * Any anemia treatment within 4 weeks before inclusion (oral iron, IV iron, transfusion, or erythropoiesis-stimulating agents). * Subjects on erythropoiesis-stimulating agents. * Requiring dialysis for the treatment of chronic kidney disease. * Any non-viral infection. * Known positive hepatitis with evidence of active disease. * Received an investigational drug within 30 days of screening. * Alcohol or drug abuse within the past 6 months. * Hemochromatosis or other iron storage disorders. * Any other laboratory abnormality, medical condition or psychiatric disorders which in the opinion of the…